Dendritic Cell Therapy

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe and can induce antitumor immunity, even in patients with advanced disease. However, clinical responses have been disappointing, with classic objective tumor response rates rarely exceeding 15%. Findings from emerging research indicate that dendritic cell-based vaccination might improve survival, advocating the implementation of alternative endpoints to assess the true clinical potency of dendritic cell-based vaccination. The implementation of the next-generation dendritic cell vaccines has improved immunogenicity, and there are emerging models being studied that combine dendritic cell vaccination with other cancer therapies.

Additional Resources:

• https://pubmed.ncbi.nlm.nih.gov/32205087
• https://pubmed.ncbi.nlm.nih.gov/33679709
• https://pubmed.ncbi.nlm.nih.gov/31020037
• https://pubmed.ncbi.nlm.nih.gov/29114544
• https://pubmed.ncbi.nlm.nih.gov/32582537
• https://pubmed.ncbi.nlm.nih.gov/30327656